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The scientific community has responded to the coronavirus disease 2019 (COVID-19) pandemic by rapidly undertaking research to find 
effective strategies to reduce the burden of this disease. Encouragingly, researchers from a diverse array of fields are collectively working 
towards this goal. Research with infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undertaken in high-
containment laboratories; however, it is often desirable to work with samples at lower-containment levels. To facilitate the transfer of infec-
tious samples from high-containment laboratories, we have tested methods commonly used to inactivate virus and prepare the sample for 
additional experiments. Incubation at 80°C, a range of detergents, Trizol reagents, and UV energies were successful at inactivating a high 
titer of SARS-CoV-2. Methanol and paraformaldehyde incubation of infected cells also inactivated the virus. These protocols can provide 
a framework for in-house inactivation of SARS-CoV-2 in other laboratories, ensuring the safe use of samples in lower-containment levels.
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The novel coronavirus, severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) emerged in December 2019 in 
Wuhan, China, and spread to the rest of the world in a few 
months causing a pandemic [1, 2]. This virus causes the coro-
navirus disease, known as COVID-19, in humans and, as of 17 
May 2020, has infected almost 5 000 000 people and caused over 
300 000 deaths [3]. Research on SARS-CoV-2 has increased ex-
ponentially since the beginning of the pandemic and will likely 
continue growing until an effective vaccine is developed. In the 
UK, and many other countries, SARS-CoV-2 is classified as a 
hazard group 3 pathogen. For handling clinical samples and 
performing experiments involving SARS-CoV-2 and other vir-
uses in general, inactivation methods are needed in order to 
work under safe conditions. Additionally, the inactivation of 
the virus allows the transfer of the material from a containment 
level (CL) 3 to a CL2 laboratory, facilitating the performance of 
experiments and increasing the number of laboratories and re-
searchers that can perform those experiments. Several methods 
of inactivation are available, but because this is a novel virus, the 
effectiveness of many of these methods on SARS-CoV-2 has not 
been tested yet. Some inactivation approaches have been tested 
on SARS-CoV, a coronavirus which spread between November 
2002 and September 2003 and whose genome presents an 80% 
shared identity with the new SARS-CoV-2 [4]. It is expected 
that the outcome of both physical and chemical inactivation 
methods used against SARS-CoV-2 will be similar to SARS-
CoV, but methods need to be validated prior to use of the new 
virus isolate.
Several methods for virus inactivation are available and the 
choice of which approach to use is often related to their com-
patibility with downstream applications. Heat inactivation has 
been used for several viruses [5, 6] and is a common method 
employed for antigen preservation of viral and bacterial patho-
gens. To preserve proteins in the sample that are related to host 
immune response, detergents and UV can be used to inactivate 
viruses [7, 8]. Detergents and Trizol are common additives in 
reagents used for virus inactivation, as well as RNA extraction 
from a range of sample types. Fixation of infected cells using 
methanol or paraformaldehyde is commonly used to preserve 
and stabilize cell morphology and can simultaneously render 
samples noninfectious [9]. UV irradiation, which inactivates 
viruses by modifying their nucleic acid structure, has been used 
successfully to inactivate many viruses, and in particular SARS-
CoV [10]. Inactivation of SARS-CoV-2 through the use of UV 
would allow the safe use of the virus within a CL2 laboratory 
and prevent the possibility of laboratory-acquired infections. 
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Here we aim to assess and describe physical and chemical inac-
tivation protocols of SARS-CoV-2.
METHODS
Cell Culture and Viruses
Vero E6 cells (C1008; African green monkey kidney cells) 
were obtained from Public Health England and maintained 
in Dulbecco’s minimal essential medium (DMEM) containing 
10% fetal bovine serum (FBS) and 0.05 mg/mL gentamycin at 
37°C with 5% CO2. SARS-CoV-2 isolate SARS-CoV-2/human/
Liverpool/REMRQ0001/2020, which was cultured from a naso-
pharyngeal swab from a patient, was passaged a further 4 times 
in Vero E6 cells. The fourth passage of virus was cultured in 
Vero E6 cells with DMEM containing 4% FBS and 0.05 mg/mL 
gentamycin at 37°C with 5% CO2 and was harvested 48 hours 
post inoculation. Virus stocks were stored at −80°C.
Virus Inactivation
Heat, detergent, and UV inactivations were performed with 
1.1 × 107 plaque forming units (PFU) of virus. Inactivations 
with Trizol and Trizol LS were performed with 2.0 ×  105 
PFU. A multiplicity of infection of 0.001 was used to infect 
cells destined for fixation using 100% ice-cold methanol or 
4% paraformaldehyde. Cells were incubated with virus for 
20 minutes at 37°C and 5% CO2, prior to the addition of 
DMEM (4% FBS, 0.05 mg/L gentamycin) and incubated for 
48 hours. Heat inactivation was performed by incubating 
300 µL of SARS-CoV-2 stock at 80°C for 1 hour. For inacti-
vation with detergents, 0.5% sodium dodecyl sulfate [SDS], 
0.5% Triton X-100, 0.5% Tween 20, or 0.5% NP-40 were 
incubated with virus for 30 minutes at room temperature. 
Inactivation with Trizol and Trizol LS used a 1:4 ratio of 
virus:Trizol reagent, which was mixed with the virus load 
and incubated at room temperature for 5 minutes. For fixa-
tion, after 48 hours the medium was removed and cells were 
removed by scraping. Cell scrapings were mixed 1:1 with 
the fixative for 30 minutes at room temperature. This was 
then centrifuged at 2500g for 5 minutes and the supernatant 
removed. Cell pellets were washed 2 times in phosphate-
buffered saline (PBS) prior to resuspension up to 300  µL 
in PBS. UV inactivation was performed using a CL1000 
UVP Crosslinker inside a microbiological safety cabinet. 
The CL-1000 UVP Crosslinker consisted of 5  ×  254  nm 
shortwave tubes, which is the recommended wavelength 
for inactivating viruses, in particular SARS-CoV [10]. 
Virus stock was added (250 µL) into wells of a 24-well plate 
and placed without its lid on top of an ice block inside the 
crosslinker. Plates were placed exactly 6  cm below the UV 
bulbs (distance measured from the bottom of the well to 
the bulbs). Inactivation was performed at a range of UV 
energy exposures (0.01 J/cm2–0.8 J/cm2). All inactivation 
procedures were performed in triplicate, with the exception 
of NP-40 which was performed in duplicate.
Virus Viability and Quantification
Heat-treated samples were evaluated for viable virus in a 50% 
tissue culture infectious dose (TCID50) assay with Vero E6 cells, 
using the entire volume of the sample. Control virus stocks con-
taining 100, 101, and 102 PFU incubated at room temperature 
for 1 hour were used to determine the limit of detection of the 
assay. TCID50 plates were passaged onto fresh cells for 4 days at 
least twice to ensure no replicative virus remained. Cells were 
monitored daily for cytopathic effect (CPE).
Virus samples treated with SDS and Triton X-100 were added 
to 15  mL of DMEM in a centrifugal concentrator (Amicon 
Ultra-15 100  kDa MWCO) and centrifuged until ≤300  µL of 
sample remained. Virus samples treated with Tween 20 and 
NP-40 were diluted in 50  mL of PBS and concentrated until 
≤300 µL of sample remained. Virus samples treated with Trizol 
reagents were diluted in 40 mL of PBS and concentrated until 
≤300  µL of sample remained. Sample was extracted and virus 
culture medium was added to a final volume of 300 µL. Viable 
virus was evaluated in a TCID50 assay as outlined above. Control 
virus stocks containing 100, 101, and 102 PFU were diluted in 
PBS and followed the above protocol with centrifugal filters to 
determine the limit of detection of the assay. To examine the di-
rect CPE of unfiltered detergent on the cells, additional controls 
with 0.05% of each detergent in the absence of virus were ex-
plored using TCID50. To determine if any viable virus remained 
in fixed cells, TCID50 assays were performed alongside an un-
fixed control. Plates were observed for CPE for 3 days and subse-
quently passaged onto fresh cells at least twice to ensure no virus 
remained. Plaque assays and TCID50 assays were performed on 
untreated virus stocks and on UV-inactivated stocks in parallel. 
TCID50 plates were passaged onto fresh cells for 3 days at least 
twice to ensure no replicative virus remained. TCID50 results 
were calculated using the Spearman and Karber method as pre-
viously described [11].
RESULTS
We first determined the limits of sensitivity for our detec-
tion method by quantifying SARS-CoV-2 at 100, 101, or 102 
PFU using TCID50 assays. This was done by quantifying viral 
titers directly or by passing the sample through a centrifugal 
column, which is used to remove the inactivation agent be-
fore assaying on cells. Virus prepared without the centrifugal 
column was detected down to dilutions of 100 PFU of SARS-
CoV-2 (Figure  1A). The limit of detection with the centrif-
ugal columns was determined to be 101 PFU of SARS-CoV-2 
(Figure  1A). Using uninfected samples containing detergents 
directly in the TCID50 assay resulted in CPE, raising the limit of 
detection (Figure 1B). Thus, the use of centrifugal columns to 
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remove cytotoxic compounds allows a lower limit of detection 
to confirm inactivation of the virus.
We then quantified virus after inactivation. SARS-CoV-2 
treated at 80°C for 1 hour was successfully inactivated. We 
passaged samples a second time to confirmed complete viral 
inactivation. Using detergents and Trizol reagents, complete 
inactivation was seen in all replicates of SDS, Triton X-100, 
NP-40, Trizol, and Trizol LS, which we again confirmed by 
passaging the supernatant to a fresh monolayer of cells to check 
for residual virus (Figure 2). However, we found virus samples 
treated with Tween 20 all remained infectious. At the 100 PFU 
dilution, CPE was observed in 2 of 3 replicates (Figure 2); how-
ever, virus was not detected in this dilution when using the cen-
trifugal columns for clean-up. CPE was seen in all other control 
wells for either treatment. In order to determine if fixation of 
infected cells using methanol or paraformaldehyde resulted in 
virus inactivation, we performed TCID50 assays using unfixed 
infected cells and fixed cells. Complete inactivation was ob-
served for both methanol and 4% paraformaldehyde fixed cells 
(Figure 3).
In order to determine if UV exposure at 254 nm would inactivate 
SARS-CoV-2, virus stocks were placed in wells of a 24-well plate 
placed on ice and exposed to varying amounts of UV energy (J/
cm2). Exposure of SARS-CoV-2 to UV light at 0.01 J/cm2 resulted 
in partial inactivation and this increased with greater UV energy ex-
posure, resulting in complete inactivation at UV energy exposures 
of more than 0.04 J/cm2 (Figure 4). A similar inactivation curve was 
seen by both TCID50 and plaque assay. No CPE was evident in fur-
ther passages in samples where inactivation was observed.
DISCUSSION
Virus inactivation can be achieved by several methods. 
However, specific methods must be chosen to comply with 
requirements for subsequent downstream experiments. We 
used a range of techniques that are often used for preserving 
antigens or immunological proteins to evaluate their ability to 
inactivate SARS-CoV-2, including a range of common deter-
gents and determining the threshold of inactivation by UV ex-
posure. The assay to assess infectious particles was also shown 
to be sensitive, in some cases down to a single infectious virus 
particle (TCID50  =  0.69 PFU/mL), and down to 10 infectious 
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Figure 1. Limit of detection of SARS-CoV-2 by different methods. A, Assay to quantify the limits of detection. Known titers of virus were prepared with (right) or without (left) 
concentrating the sample in a centrifugal column. Quantification of controls was performed using TCID50. Lower limit of detection was 3.16 TCID50/mL: (n = 3; mean ± SEM). 
B, Cytotoxicity from uninfected control samples diluted in a TCID50 assay (n = 3; mean ± SEM). Abbreviations: PFU, plaque-forming unit; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2; SDS, sodium dodecyl sulfate; SEM, standard error of the mean; TCID50, 50% tissue culture infectious dose.
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Figure 2. The proportion of SARS-CoV-2 inactivation assays with CPE. Samples 
were either diluted for assays (left) or inactivation agent removed using centrifugal 
columns (right). Control samples with 100, 101, and 102 PFU of SARS-CoV-2 were 
used as positive controls and to determine the limit of detection for each method. 
Abbreviations: CPE, cytopathic effect; PFU, plaque-forming unit; SARS-CoV-2, se-
vere acute respiratory syndrome coronavirus 2; SDS, sodium dodecyl sulfate.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article/doi/10.1093/infdis/jiaa507/5892951 by guest on 28 August 2020
4 • jid 2020:XX (XX XXXX) • Patterson et al
8
A
1.0
0.5
Pr
op
or
tio
n 
w
ith
 C
PE
0.0
B
6
4
T
C
ID
50
 (l
og
10
)/
m
L
2
0
Condition
Co
nt
ro
l
M
eth
an
ol
4%
 pa
ra
fom
ald
eh
yd
e
Condition
Co
nt
ro
l
M
eth
an
ol
4%
 pa
ra
fom
ald
eh
yd
e
Figure 3. Effect of fixation on infectious virus in cells. A, TCID50 assay comparing untreated infected cells with fixed infected cells. Lower limit of detection was 0.5 TCID50 
(log10)/mL (n = 3; mean ± SEM). B, The proportion of inactivation assays with CPE. Abbreviations: CPE, cytopathic effect; SEM, standard error of the mean; TCID50, 50% tissue 
culture infectious dose.
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Figure 4. Quantification of SARS-CoV-2 following exposure to different energies of UV light. A, The concentration of viable SARS-CoV-2 following exposure to UV light 
measured by TCID50 assay. Lower limit of detection was 0.5 TCID50(log10)/mL. B, The concentration of viable SARS-CoV-2 following exposure to UV measured by plaque assay. 
Both assays confirmed the complete inactivation of the sample after exposure to 0.04 J/cm2 or higher UV energy. Results are expressed as mean ± SEM (n = 3). Abbreviations: 
PFU, plaque-forming unit; SEM, standard error of the mean; TCID50, 50% tissue culture infectious dose.
particles/mL where a centrifugal column is used to concentrate 
the sample.
Physical inactivation can be performed using heat or expo-
sure to UV. Heat inactivates the virus by denaturing the struc-
ture of the proteins, affecting the attachment and replication of 
the virus in the host cell [12]. In this study, SARS-CoV-2 was 
successfully inactivated with a temperature of 80°C. Lower 
temperatures used to inactivate SARS-CoV showed that 56°C 
is only effective in the absence of fetal calf serum and temper-
atures up to 75°C are needed for successful inactivation of in-
fected clinical samples [9, 10]. However, heat inactivation is not 
recommended in a clinical setting for immunological assays 
because it can interfere with the analysis of antibodies against 
SARS-CoV-2 [13] and diagnosis of patient samples using 
RT-PCR, which could potentially lead to a false-negative diag-
nosis [14, 15].
UV light causes genetic damage by inducing pyrimidine di-
mers or by producing reactive oxygen species [16]. While other 
researchers have investigated UV inactivation of viruses by 
looking at length of exposure, here we have inactivated virus 
based on the energy exposure. As UV lamps age, their irra-
diance output begins to decline. The crosslinker in this study 
has an inbuilt sensor allowing the unit to determine the exact 
amount of UV energy delivered. Therefore, to maintain consist-
ency in experiments over time, it is recommended to inactivate 
virus based on the UV energy exposure rather than time of ex-
posure. UVC exposure at 3 cm for 15 minutes has been shown 
to inactivate SARS-CoV, whereas UVA light was not effective 
[10, 17]. Here, we have demonstrated a method by which SARS-
CoV-2 can be rendered noninfectious through application of 
UV energy >0.04 J/cm2. Nevertheless, we recommend that for 
any changes in cell substrate, virus, or for new operators, the 
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validation process is repeated to ensure that no infectious virus 
remains after UV inactivation.
Chemical inactivation can be performed using detergents and 
Trizol reagents, and we successfully demonstrated this with 5 dif-
ferent compounds: 0.5% SDS, 0.5% Triton X-100, 0.5% NP-40, 
Trizol, and Trizol LS. Conversely, Tween 20 did not inactivate 
SARS-CoV-2 under the same conditions. Detergents disrupt the 
lipid coat of enveloped viruses and are often present in lysis buf-
fers of commercial nucleic acid extraction kits. These detergents 
typically do not affect proteins so they can be used in down-
stream procedures preserving their native structure. Our findings 
are consistent with previous studies showing that 0.1% SDS with 
0.1% NP-40 [10] and 0.3% tri(n-butyl)phosphate (TNBP) with 
1.0% Triton X-100 [8] could inactivate SARS-CoV. Recent studies 
on SARS-CoV-2 showed that several lysis buffers from extrac-
tion kits like ATL (1%–10% SDS) and VXL (30%–50% guan-
idine hydrochloride and 1%–10% Triton X-100) from Qiagen 
[14] and others containing guanidine hydrochloride [18] and 
guanidinium [19] inactivated the virus. Several RNA extraction 
kits contain a lysis buffer effective at inactivating SARS-CoV-2 
[20]. This is convenient for downstream experiments like qRT-
PCR used for diagnosis. However, not all the laboratories may 
have access to these kits. The use of centrifugal columns to re-
move cytotoxic compounds has been successfully employed in 
this study, correlating to previous results [5, 21]; however, this 
raises the threshold of detection by approximately 10 fold. An al-
ternative method is to dilute detergent to levels that are no longer 
cytotoxic. However, in our hands, this decreased our ability to 
detect infectious virus by 100–1000 fold. Therefore, our method 
using centrifugal columns was more sensitive.
Fixation using 100% methanol or 4% paraformaldehyde is 
often used for downstream immunohistochemical techniques 
or methods that require stabilization of the cellular structure. 
While methanol acts to precipitate large proteins and will per-
meabilize cells allowing the assessment of intracellular struc-
tures [22], formaldehyde reacts with amines found on proteins 
and nucleic acids and forms stable methylene bridge crosslinks, 
further preserving cell structure but potentially blocking 
epitopes [23]. Here we have shown that both techniques can 
also inactivate SARS-CoV-2, rendering fixed samples safe to 
process in CL2 conditions.
With the increasing interest in COVID-19, many re-
searchers are now applying their knowledge and expertise 
to different topics to address this global problem. However, 
not all researchers have access to containment facilities 
and essential equipment is not often available at biosafety 
levels required to work safely with SARS-CoV-2. The inac-
tivation methods described here will contribute to help di-
verse research groups perform their downstream work on 
SARS-CoV-2.
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